Monopar Therapeutics Inc. announced on April 29, 2025, that data on the long-term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2025.
The EASL Congress, scheduled from May 7 – 10, 2025, in Amsterdam, Netherlands, is a premier event in hepatology. Late-breaker abstracts are selected for presenting the latest, highly significant research findings with the potential to substantially impact the field.
The abstract, titled 'Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline,' will be presented by Dr. Karl Heinz Weiss. This selection indicates the compelling nature of the ALXN1840 data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.